Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
Sep 27 SAVA Why Cassava Sciences Stock Dived by Almost 11% Today
Sep 27 LLY Stocks to Buy and Hold for 5 Years
Sep 27 SAVA Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims
Sep 27 LLY 21 Stocks to Play a ‘Magical Moment’ in Healthcare
Sep 27 PFE Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
Sep 27 LLY Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
Sep 27 PFE Agios cut at Leerink on overhang from Pfizer’s Oxbryta withdrawal
Sep 27 PFE Bayer Submits Application for Label Expansion of Prostate Cancer Drug
Sep 27 SAVA Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
Sep 27 PFE Pfizer: A 6% Yielding Value Deal
Sep 27 PFE 4 High Earnings Yield Stocks That Value Investors Should Buy Now
Sep 27 SAVA Cassava Sciences shares drop in pre-open trade after $40 mln SEC settlement
Sep 27 SAVA These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava Sciences, Trump Media, HP Inc., and More
Sep 27 SAVA SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
Sep 27 PFE Buy These 4 S&P 500 Year-to-Date Laggards With Solid Near-Term Upside
Sep 27 SAVA Cassava settles SEC charges related to Alzheimer’s candidate for $40M
Sep 27 SAVA Update: Cassava Sciences Pays $40 Million to Settle SEC Charges; Shares Drop Pre-Bell
Sep 27 LLY Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason
Sep 26 SAVA Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
Sep 26 SAVA Cassava Sciences Resolves SEC Investigation
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags